Verbascoside (Synonyms: ベルバスコシド; Acteoside; Kusaginin; TJC160)

Name: Verbascoside
Brand: MedChemExpress
SKU: HY-N0021
Rating: 5.0 (15 reviews)

製品番号: HY-N0021 純度: 99.83%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Verbascoside is isolated from Acanthus mollis, acts as an ATP-competitive inhibitor of PKC, with an IC₅₀ of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 61276-17-3

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 96	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 96	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$70	在庫あり	Estimated Time of Arrival: December 31
10 mg	$112	在庫あり	Estimated Time of Arrival: December 31
25 mg	$224	在庫あり	Estimated Time of Arrival: December 31
50 mg	$345	在庫あり	Estimated Time of Arrival: December 31
100 mg	$483	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 15 publication(s) in Google Scholar

Other Forms of Verbascoside:

Verbascoside (Standard) 在庫あり
cis-Verbascoside お問い合わせ

顧客検証

In Vivo Efficacy Study

Histological Imaging/Staining

Cell Proliferation/Viability Assay

: Verbascoside purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Jun 23;60(12):1751-1767.e9. [Abstract]; Verbascoside (VB; 10 μM; 24 h) did not interfere with CHI3L1-STAT3 interaction.

: Verbascoside purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 May 6:331:118272. [Abstract]; Bar charts showing the length of the regenerating fin of zebrafish exposure to different concentrations of Verbascoside (40, 80, 100, 150 mg/mL) ingredients at 2 dpa.

: Verbascoside purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Mar;23(5):537-554. [Abstract]; Verbascoside (CD44 inhibitor; 1.87 μg/ear; 0.2 mL administered into the middle ears) in Six weeks old male Sprague-Dawley (SD) rats could remarkably ameliorate these symptoms could ameliorate the development of middle ear cholesteatoma.

: Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.; Verbascoside (75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice at a dose of 150 mg/kg/d (db-150VB) significantly lowered the fasting blood glucose (FBG) level and albumin-to-creatinine ratio (ACR) compared to db/db mice.

: Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.; Verbascoside (VB; 75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice at a dose of 150 mg/kg/d (db-150VB) alleviated kidney pathologic damage, which was characterized by mesangial matrix expansion and glomerulosclerosis compared to diabetic mice.

: Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.; Verbascoside (VB; 75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice restored the decreased expression of nephrin and podocin.

: Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.; Verbascoside (VB; 75, 150 mg/kg; po; daily for 4 weeks) 8 weeks Male C57BLKS/J db/db and db/+ mice effectively reduced the IL-6, CXCL10, and MCP-1 protein expression in renal tissues, especially in the 150 mg/kg/d dose group.

: Verbascoside purchased from MedChemExpress. Usage Cited in: Acta medica mediterr . 2023 Feb 28.; The cytotoxic effect of verbascoside (25, 50, 75, 100, 200, 300 and 400 μM) on MPC5 for 24 h determined by Cell Counting Kit-8 assay.

PKC アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

HSV アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

HSV-1 HSV-2 HSV

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[1]

PKC

25 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.81 3 Compound: 2	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
A549	IC₅₀	5.81 3 Compound: 2	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
A549	IC₅₀	5.81 3 Compound: 2	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
Erythrocyte	IC₅₀	28 3 Compound: 6	Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs	[PMID: 12828473]
Erythrocyte	IC₅₀	28 3 Compound: 6	Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs	[PMID: 12828473]
HCT-15	IC₅₀	2.73 3 Compound: 2	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
HCT-15	IC₅₀	2.73 3 Compound: 2	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
Erythrocyte	IC₅₀	28 3 Compound: 6	Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs	[PMID: 12828473]
HEp-2	EC₅₀	0.8 6 Compound: 1, verbascoside	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	0.8 6 Compound: 4	Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 9784173]
HCT-15	IC₅₀	2.73 3 Compound: 2	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
HEp-2	EC₅₀	9.7 6 Compound: 1, verbascoside	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	IC₅₀	44 6 Compound: 1, verbascoside	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	0.26 6 Compound: 1, verbascoside	Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	EC₅₀	0.26 6 Compound: 1, verbascoside	Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	71 6 Compound: 1, verbascoside	Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Cytotoxicity against HSV2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	0.8 6 Compound: 1, verbascoside	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	0.8 6 Compound: 1, verbascoside	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	76.9 6 Compound: 1, verbascoside	Cytotoxicity against RSV long infected human Hep2 cells after 3 days Cytotoxicity against RSV long infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	76.9 6 Compound: 1, verbascoside	Cytotoxicity against RSV long infected human Hep2 cells after 3 days Cytotoxicity against RSV long infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	0.8 6 Compound: 4	Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 9784173]
HEp-2	EC₅₀	9.7 6 Compound: 1, verbascoside	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	IC₅₀	71 6 Compound: 1, verbascoside	Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Cytotoxicity against HSV2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	76.9 6 Compound: 1, verbascoside	Cytotoxicity against RSV long infected human Hep2 cells after 3 days Cytotoxicity against RSV long infected human Hep2 cells after 3 days	[PMID: 9599250]
Hepatocyte	IC₅₀	4.6 3 Compound: 5	Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
HEp-2	IC₅₀	76.9 6 Compound: 4	Cytotoxicity against human Hep2 cells Cytotoxicity against human Hep2 cells	[PMID: 9784173]
J774.A1	EC₅₀	4.9 x 10^-4 41 Compound: 2	Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay	[PMID: 16309308]
HEp-2	EC₅₀	9.7 6 Compound: 1, verbascoside	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
L1210	IC₅₀	13 3 Compound: 1	Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 1812212]
HEp-2	IC₅₀	108 6 Compound: 1, verbascoside	Cytotoxicity against human Hep2 cells administered 3 hrs postinfection Cytotoxicity against human Hep2 cells administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	108 6 Compound: 1, verbascoside	Cytotoxicity against human Hep2 cells administered 3 hrs postinfection Cytotoxicity against human Hep2 cells administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	44 6 Compound: 1, verbascoside	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
L929	IC₅₀	17.8 6 Compound: 5	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
HEp-2	IC₅₀	44 6 Compound: 1, verbascoside	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
SK-MEL-2	IC₅₀	8.52 3 Compound: 2	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
Hepatocyte	IC₅₀	4.6 3 Compound: 5	Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
HEp-2	IC₅₀	71 6 Compound: 1, verbascoside	Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Cytotoxicity against HSV2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	76.9 6 Compound: 4	Cytotoxicity against human Hep2 cells Cytotoxicity against human Hep2 cells	[PMID: 9784173]
SK-OV-3	IC₅₀	7.61 3 Compound: 2	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
J774.A1	EC₅₀	4.9 × 10^-4 41 Compound: 2	Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay	[PMID: 16309308]
Hepatocyte	IC₅₀	4.6 3 Compound: 5	Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
L1210	IC₅₀	13 3 Compound: 1	Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 1812212]
L929	IC₅₀	17.8 6 Compound: 5	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
J774.A1	EC₅₀	4.9 x 10^-4 41 Compound: 2	Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay	[PMID: 16309308]
SK-MEL-2	IC₅₀	8.52 3 Compound: 2	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
SK-OV-3	IC₅₀	7.61 3 Compound: 2	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
L1210	IC₅₀	13 3 Compound: 1	Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 1812212]
L929	IC₅₀	17.8 6 Compound: 5	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
P388	ED₅₀	2.6 6 Compound: 1	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 2380718]
Peritoneal macrophage cell	IC₅₀	> 100 3 Compound: 5	Inhibition of LPS-induced TNFalpha production in ddY mouse peritoneal macrophages Inhibition of LPS-induced TNFalpha production in ddY mouse peritoneal macrophages	[PMID: 20159656]
Peritoneal macrophage cell	IC₅₀	> 100 3 Compound: 5	Inhibition of LPS-induced nitric oxide production in ddY mouse peritoneal macrophages Inhibition of LPS-induced nitric oxide production in ddY mouse peritoneal macrophages	[PMID: 20159656]
SK-MEL-2	IC₅₀	8.52 3 Compound: 2	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
SK-OV-3	IC₅₀	7.61 3 Compound: 2	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]

体外実験

Verbascoside acts as an ATP-competitive inhibitor of PKC, with an IC₅₀ of 25 μM. Verbascoside shows K_is of 22 and 28 μM with respect to ATP and histone, respectively. Verbascoside has potent antitumor activity against L-1210 cells, with an IC₅₀ of 13 μM^[1]. Verbascoside (5, 10 μM) suppresses 2,4-dinitrochlorobenzene (DNCB)-induced T cell costimulatory factors CD86 and CD54, proinflammatory cytokines, and NFκB pathway activation in THP-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Verbascoside (1%) reduces the overall scratching behavior incidence as well as the severity of the skin lesions in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) mice model. Verbascoside also blocks DNCB-induced expression of proinflammatory cytokine TNF-α, IL-6, and IL-4 mRNA in skin lesions^[2]. Verbascoside (50, 100 mg/kg, i.p.) does not modify chronic constriction injury (CCI)-induced cold allodynia. Verbascoside (200 mg/kg, i.p.) decreases hyper-sensitivity to cold stimulus, acetone, on day 3 in rats. Verbascoside also significantly reduces behavioral changes associated with neuropathy. Moreover, Verbascoside decreases Bax and increases Bcl-2 on day 3^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

624.59

分子式

C₂₉H₃₆O₁₅

CAS 番号

61276-17-3

Appearance

Solid

Color

White to yellow

SMILES

O[C@@H]([C@H](OCCC1=CC(O)=C(O)C=C1)O2)[C@H]([C@@H]([C@H]2CO)OC(/C=C/C3=CC(O)=C(O)C=C3)=O)O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (160.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (160.11 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6011 mL	8.0053 mL	16.0105 mL
5 mM	0.3202 mL	1.6011 mL	3.2021 mL
10 mM	0.1601 mL	0.8005 mL	1.6011 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

純度とドキュメンテーション

純度: 99.83%

Select Batch:

データシート (282 KB) SDS (396 KB)

COA (253 KB) HNMR (345 KB) LCMS (99 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Herbert JM, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. J Nat Prod. 1991 Nov-Dec;54(6):1595-600. [Content Brief]

[2]. Li Y, et al. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. Int Arch Allergy Immunol. 2018;175(4):220-230. [Content Brief]

[3]. Amin B, et al. The Effect of Verbascoside in Neuropathic Pain Induced by Chronic Constriction Injury in Rats. Phytother Res. 2016 Jan;30(1):128-35. [Content Brief]

細胞実験 ^[1]	The lymphocytic mouse leukemia L1210 cells (ATCC, CCL 219) are plated sparsely at 10⁴ cells per well in 24-well cluster plates in Dulbecco’s modified Eagle medium containing 10% fetal calf serum, 4 mM glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin sulfate, and Verbascoside (solubilized in DMSO). After a 2-day incubation period at 37°C in a humidified atmosphere (5% CO₂ in air), growth is monitored by counting cell numbers in a Coulter-counter. IC₅₀ values are calculated on the basis of the linear regression lines established for each compound tested^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[2]	Rats^[2] To induce atopic dermatitis (AD)-like symptoms, 2,4-dinitrochlorobenzene (DNCB) is used. Briefly, the dorsal hair of the mice is removed using an electronic clipper 2 days before DNCB treatment. An application of 200 µL of 1% DNCB (in acetone:olive oil = 4:1) is made to the shaved dorsal skin for sensitization. The repeated challenge is performed on the same site with 0.2% DNCB once every 3 days for about 2 weeks. The mice are divided into 4 groups (n = 6 per group): (1) vehicle-treated controls, (2) DNCB-treated only, (3) 1% Verbascoside (in acetone:olive oil 4:1)-treated only, and (4) DNCB + 1% Verbascoside-treated group^[2]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Herbert JM, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. J Nat Prod. 1991 Nov-Dec;54(6):1595-600. [Content Brief] [2]. Li Y, et al. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. Int Arch Allergy Immunol. 2018;175(4):220-230. [Content Brief] [3]. Amin B, et al. The Effect of Verbascoside in Neuropathic Pain Induced by Chronic Constriction Injury in Rats. Phytother Res. 2016 Jan;30(1):128-35. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.6011 mL	8.0053 mL	16.0105 mL	40.0263 mL
	5 mM	0.3202 mL	1.6011 mL	3.2021 mL	8.0053 mL
	10 mM	0.1601 mL	0.8005 mL	1.6011 mL	4.0026 mL
	15 mM	0.1067 mL	0.5337 mL	1.0674 mL	2.6684 mL
	20 mM	0.0801 mL	0.4003 mL	0.8005 mL	2.0013 mL
	25 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6011 mL
	30 mM	0.0534 mL	0.2668 mL	0.5337 mL	1.3342 mL
	40 mM	0.0400 mL	0.2001 mL	0.4003 mL	1.0007 mL
	50 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8005 mL
	60 mM	0.0267 mL	0.1334 mL	0.2668 mL	0.6671 mL
	80 mM	0.0200 mL	0.1001 mL	0.2001 mL	0.5003 mL
	100 mM	0.0160 mL	0.0801 mL	0.1601 mL	0.4003 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Verbascoside Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Verbascoside61276-17-3Acteoside Kusaginin TJC160TJC160TJC 160TJC-160PKCApoptosisBacterialHSVProtein kinase CHerpes simplex virusInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Verbascoside (Synonyms: ベルバスコシド; Acteoside; Kusaginin; TJC160)

カスタマーレビュー

Other Forms of Verbascoside:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

PKC アイソフォーム固有の製品をすべて表示:

HSV アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Verbascoside Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Verbascoside (Synonyms: ベルバスコシド; Acteoside; Kusaginin; TJC160)

カスタマーレビュー

Other Forms of Verbascoside:

Verbascoside 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

PKC アイソフォーム固有の製品をすべて表示:

HSV アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Verbascoside 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Verbascoside Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report